Photoreceptor

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

Retrieved on: 
Tuesday, October 24, 2023
Well, International Symposium on Endovascular Therapy, AAV, Rhodopsin, RNA, Congress, Photoreceptor, PCR, Research, Retinal, RHO, Disease, Glial fibrillary acidic protein, Retina, GFAP, Eye, Paratriathlon, Patient, Gene expression, Vaccine

CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of Prime Editors to efficiently and precisely correct the predominant mutations that cause rhodopsin associated autosomal dominant retinitis pigmentosa (RHO adRP). The data were presented today at the International Symposium on Retinal Degeneration 2023 Congress (RD2023) in Costa del Sol, Spain.

Key Points: 
  • The data were presented today at the International Symposium on Retinal Degeneration 2023 Congress (RD2023) in Costa del Sol, Spain.
  • “The data presented today are the first proof-of-concept data for Prime Editing’s application in treating ophthalmological indications, and highlight the ability of Prime’s novel, dual AAV delivery platform to efficiently deliver Prime Editors to the eye,” said Jeremy Duffield, M.D., Ph.D., Chief Scientific Officer of Prime Medicine.
  • In today’s presentation at RD2023, Prime Medicine shared findings from in vivo studies in humanized mice with its Prime Editors targeting these prevalent RHO mutations.
  • Efficient delivery of Prime Editors by dual AAV to human (retinal explants) and murine (in vivo) photoreceptors.

Generation Bio Reports Business Highlights and Third Quarter 2021 Financial Results

Retrieved on: 
Wednesday, November 10, 2021
Gene, ESGCT, G&A, Private Securities Litigation Reform Act, Form 10-K, Tissue, European Society of Gene and Cell Therapy, RNA transfection, Type 5, R, Security (finance), Generation, Congress, VIII, D, COVID-19, Research, Annual report, Retina, U.S. Securities and Exchange Commission, Photoreceptor, GLOBE, Cell, Gene editing, DNA, RES, IND, Pharmaceutical industry, Vaccine

(Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and third quarter 2021 financial results.

Key Points: 
  • (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and third quarter 2021 financial results.
  • R&D Expenses: Research and development (R&D) expenses were $22.0 million for the quarter ended September 30, 2021, compared to $15.3 million for the quarter ended September 30, 2020.
  • G&A Expenses: General and administrative (G&A) expenses were $9.7 million for the quarter ended September 30, 2021, compared to $5.7 million for the quarter ended September 30, 2020.
  • Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases.